Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 12
Submit an article Journal homepage
148
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Are chronic myeloid leukemia patients ready to stop long-term treatment?

Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy; Correspondence[email protected]
&
Fabio EfficaceData Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy
Pages 2976-2978 | Received 25 Mar 2017, Accepted 06 May 2017, Published online: 23 May 2017

References

  • Caldemeyer L, Akard LP. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma. 2016;57:2739–2751.
  • Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006;47:1–7.
  • Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23.
  • Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.
  • Richter J, Mahon FX, Guilhot J, et al. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial. Haematologica. 2016;101:22.
  • Saglio G, Masszi T, Gomez Casares MT, et al. Results from ENESTfreedom: treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase. Haematologica. 2016;101:339.
  • Richter J, Soderlund S, Lubking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–2823.
  • Park JS, Lee SE, Jeong SH, et al. Change of health-related profiles after imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma. 2015;12:1–7.
  • Breccia M, Efficace F, Sica S, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leukemia Research. 2015;39:1055–1059.
  • Boquimpani CM, Szczudlo T, Mendelson E, Benjamin K, Masszi T. Attitudes and perceptions of patients with chronic myeloid leukemia in chronic phase toward treatment-free remission (TFR). Blood. 2014; 124:abstract 4547.
  • Goldberg S, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. Blood. 2015;126:abstract 1584.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.